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The effects of various protein kinase C (PKC) inhibitors on NADPH oxi- 
dase (NO) activation by the phorbol ester PMA and by the chemotactic peptide 
FMLP were studied. H-7 reduced the effects of both stimuli in human neutro- 
phils (HN) and HL-60 cells by 13-63%. Polymyxin B did not inhibit NO activa- 
tion by PMA and FMLP in HN and reduced the effects of both stimuli in HL-60 
cells by 27-55%. Retinal and retinoic acid enhanced the effects of PMA and 
FMLP in HL-60 cells and of FMLP in HN up to 4.5-fold. In contrast, retinoic 
acid inhibited the effect of PMA in HN, In the presence of cytochalasin B, re- 
tinal inhibited the effect of FMLP in HN, whereas retinoic acid inhibited NO 
activation by FMLP in both cell types. The dual PKC/calmodulin inhibitors t r i -  
fluoperazine and W-7 abolished NO activation by PMA and FMLP in HN and HL-60 
cells. Thus, the effects of PKC inhibitors on NO activation exhibit (I) cell 
type specificity, (2) stimulus dependency and (3) no correlation with in vitro 
inhibition of PKC. Our results suggest that studies with PKC inhibitors pres- 
ently available cannot clarify the role of PKC in NO activation. ~1988Ac~d .... 
Press, Inc. 
Human neutrophils possess an NADPH oxidase which catalyzes 0 2" formation 
and can be activated by cell-permeable diacylglycerol and PMA via PKC [ I ,2 ]  
and by the chemotactic peptide, FMLP [3].  The mechanism by which FMLP act i -  
vates 0 2 - formation is not known. There is a debate concerning the involvement 
of PKC in ce l lu la r  activation by FMLP [3]. In recent studies, certain PKC 
* To whom correspondance should be addressed. 
ABBREVIATIONS: 
CB, cytochalasin B; FMLP, N-formyl-L-methionyl-L-leucyl-L-phenylalanine; H-7, 
1-(5-isoquinolinesulfonyl)-2-methylpiperazine; 02-, superoxide anion; PKC, 
protein kinase C; PMA, 4B-phorbol 12-myristate 13-acetate; TFP, trifluoper- 
azine; W-7, N-(6-aminohexyl)-5-chloro-l-naphthalenesulfonamide. 
585 
0006-291X/88 $1.50 
Copyright © 1988 by Academic Press, Inc. 
All rights of reproduction i  any form reserved. 
Vol. 152, No. 2, 1988 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 
inhibitors were reported to inhibit PMA- but not receptor mediated 02 - forma- 
tion, suggesting that NADPH oxidase activation by FMLP may be independent of 
PKC [4,5]. Furthermore, PKC-independent activation of NADPH oxidase in cell- 
free systems was demonstrated by us and others [6,7]. In contrast, a PKC inhi- 
bitor prevented the chemotactic response of neutrophils towards FMLP [8]. 
The diff iculties in the interpretion of studies with PKC inhibitors in 
intact cells have been discussed in our recent study [9]. We reported that 
various PKC inhibitors failed to inhibit receptor-mediated platelet aggrega- 
tion and differentially inhibited activation by a cell-permeable diacylglyce- 
rol. We concluded that the failure of PKC inhibitors to suppress cellular 
activation does not necessarily exclude a role of PKC in this process. There- 
fore, studies with PKC inhibitors should desirably include (1) various stim- 
uli, (2) chemically unrelated PKC inhibitors and, if possible, (3) different 
cell types. 
We investigated the effects of the PKC inhibitors, H-7 [10], polymyxin B 
[11], retinal [12,13], retinoic acid [14], and of the dual PKC/calmodulin in- 
hibitors, TFP and W-7 [15,16], on 02 - formation in human neutrophils as well 
as in differentiated HL-60 cells. NADPH oxidase was stimulated by PMA, FMLP 
and FMLP plus CB, the latter agent potentiating the effect of FMLP by affect- 
ing the state of actin polymerization [17]. We report here on differential, 
stimulus-dependent inhibition or stimulation of 02 - formation by PKC inhibi- 
tors, suggesting that studies with PKC inhibitors presently available are not 
suitable to elucidate the role of PKC in NADPH oxidase activation. 
MATERIALS AND METHODS 
H-7, W-7, TFP, polymyxin B, retinal (all trans), retinoic acid (type XX, 
all trans), PMA, FMLP, CB, superoxide dismutase and ferricytochrome C (type 
I I I )  were obtained from Sigma Chemie (Taufkirchen, F.R.G.). Dibutyryl cyclic 
AMP was purchased from Pharma Waldhof (DUsseldorf, F.R.G.). All cell culture 
media and Ficoll-Hypaque were obtained from Biochrom (Berlin, F.R.G.). Stock 
solutions of W-7 (20 mM), retinoids (10 mM), PMA (10 mg/ml), FMLP (10 mM) and 
CB (1 mg/ml) were prepared in dimethyl sulfoxide. Retinoids were stored in the 
dark at 4°C. Polymyxin B and H-7 (30 mM) were dissolved in the buffer de- 
scribed below. 
Heparinized blood was obtained by venous puncture from healthy volun- 
teers of both sexes who had taken no drugs for at least 3 weeks. Neutrophils 
were isolated by dextran sedimentation and centrifugation through Ficoll-Hy- 
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paque L7]. Cell preparations consisted of more than 984 viable neutrophils as 
judged by trypan blue dye exclusion. 
HL-60 cel ls were grown in suspension culture in RPMI-1640 medium supple- 
mented with i0~ (v/v) horse serum, 14 (v/v) non-essential amino acids, 2 mM 
L-glutamine, 50 U/ml pen ic i l l in  and 50 ~g/ml streptomycin in a humidified at- 
mosphere with 7~ CO at 37°C. To induce-dif ferentiat ion, cel ls were seeded at 
a density of i0 ~ ce~Is/ml and were cultured for 48 h in the medium supplement- 
ed with 0.2 mM dibutyryl cycl ic AMP [18]. Pappenheim stains showed that the 
di f ferent iated HL-60 cel ls consisted of more than 95~ myelocytes or cells be- 
yond this  stage. 
NADPH oxidase-catalyzed 09" formation was monitored at 550 nm by contin- 
uous measurement of ferricytoch~ome C reduction inhibita~le by superoxide dis- 
mutase. Reaction mixtures ( i  ml) contained 2.5-5.0 x i0 u cel ls ,  I00 ~M fer r i -  
cytochrome C, 0.5~ dimethyl sulfoxide and a buffer consisting of 138-mM NaCl, 
6 mM KCl, i mM MgCI2, i mM CaCl 2, i mM Na2HPO 4, 5 mM NaHC03, 5.5 mM glucose 
and 20 mM HEPES, pH 7.4.  Reaction mixtures were preincubated-for 2 min in the 
absence or presence of CB and inhibitors at 37°C. Op" formation was in i t iated 
by the addition of PMA or FMLP. Vma x of 02 - formatiSn was calculated from the 
l inear parts of absorbance curves. 
RESULTS 
The effects of various PKC inhibitors on 02" formation in neutrophils 
and HL-60 cel ls are summarized in Tables i and 2. In preliminary experiments, 
the concentrations of PMA, FMLP and CB used in this  study were found to be 
maximally effect ive to stimulate NADPH oxidase (data not shown). In order to 
prevent cell  damage by dimethyl sulfoxide, W-7, TFP and retinoids had to be 
added to assay mixtures in a maximum volume of 0.5~ (v/v) .  Thus, the maximum 
Table I: Activation of NADPH oxidase by PMA in human neutrophils and in HL-60 
cells and its modulation by various inhibitors of protein kinase C 
Inhibitor NADPH oxidase activity 
(in ~ of control) 
neutrophils HL-60 cells 
None i00 (8) i00 (8) 
H-7 (300 ~M) 46 ± 7 (6) 37 ± 7 (8) 
Polymyxin B (300 pM) 93 ± 8 (6) 73 ± 11 (8) 
Retinal ( 50 ~M! 97 ± 33 (9) 287 ± 70 (6) 
Retinoic acid ( 50 ~M) 45 ± 20 (7) 206 ± 68 (7) 
(100 0 (3) 0 (3) 
W-7 (100 0 (3) 0 (3) 
NADPH oxidase-catalyzed 02 - formation was measured as described under 
MATERIALS AND METHODS. Vm~  of 07 - formation in the presence of various PKC 
inhibitors is referred ~C-that 3n the absence of these compounds. In the 
absence of inhibitors neut~phils and HL-60 cells generated 69.0 • 17.6 and 
15.0 ± 3.7 nmoles of 02-/10 cells/min upon stimulation with PMA (I00 ng/ml). 
The numbers in parentheses indicate the number of individual blood donors and 
batches of HL-60 cells investigated. Data are the mean ± S.E.M. 
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Table 2: Activation of NADPH oxidase by FMLP in human neutrophils and in HL-60 cells and 
its modulation by various inhibitors of protein kinase C 
Inhibitor NADPH oxidase activity 
(in ~ of control) 
neutrophils HL-60 cells 
- CB + CB - CB + CB 
None i00 (8) 100 (8) i00 (8) i00 (8) 
H-7 (300 ~M) 87 ± 12 (5) 106 ± 24 (5) 58 ± 18 (4) 70 ± I i  (4) 
Polymyxin B (300 ~M) 97 ± 17 (5) 96 ± 20 (5) 45 ± 17 (4) 58 ± 7 (6) 
Retinal ( 50 ~M) 158 ± 15 (5) 41 ± 22 (4) 445 ± 131 (3) 185 ± 33 (4 I 
Retinoic acid ( 50 pM) 244 ± i00 (3) 55 ± 21 (4) 334 ± 47 (3) 76 ± 20 (5 l 
TFP (100 ~M) 0 (3) 0 (3) 0 (3) 0 (3) 
W-7 (I00 ~M) 0 (3) 0 (3) 0 (3) 0 (3) 
NADPH oxidase-catalyzed 02 - formation was measured as described under MATERIALS AND METHODS. 
Vmax of 02 - formation in the presence of various PKC inhibitors is referred to that in the 
absence of these compounds. In the absence of inhibitors, neutrophils generated 17.5 -+ 5.4 
and 53.8 ± 13.5 nmoles of 02-/107 cells/min upon stimulation with FMLP (I~M) and FMLP (i I~M) 
plus CB (1 ~g/ml), respectively. HL-60 cells produced 7.3 -+ 2/5 and 21.9 + 4.8 nmoles of 
02-/107 cells/min upon exposure to these stimuli. The numbers in parentheses indicate the 
number of individual blood donors and batches of HL-60 cells investigated. Data are the mean 
-+ S.E.M. 
concentrations of these compounds obtainable in the assays were in the range 
of those required for  half-maximal inh ib i t ion  of PKC in v i t ro  [12-16]. The 
concentrations of H-7 and polymyxin B present in the assays were 50- and 150- 
fo ld higher than those required for  half-maximal inh ib i t ion  of PKC in vitro 
[I0,11]. 
H-7 inhib i ted PMA-induced 02 - formation in neutrophils and in HL-60 
cel ls  by 54 and 63~, respect ively.  Polymyxin B reduced the ef fect  of PMA in 
neutrophi ls only marginally and inhibited the one of PMA in HL-60 cel ls  by 
27~. Retinal did not af fect  NADPH oxidase act ivat ion by PMA in neutrophils and 
potentiated the e f fect  of PMA in HL-60 ce l ls .  In contrast, re t ino ic  acid in- 
h ibi ted the e f fect  of PMA in neutrophils by 55~ and enhanced the ef fect  of PMA 
in HL-60 cel ls  more than twice. TFP and W-7 completely prevented PMA-induced 
02 - formation in both cel l  types. 
In neutrophi ls,  H-7 did not inh ib i t  NADPH oxidase act ivat ion by FMLP + 
CB and reduced the ef fect  of FMLP in the absence of CB by 13~. In contrast, H- 
7 reduced the FMLP-induced 02 - formation in HL-60 cel ls  by 30 and 42~ in the 
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presence and absence of CB, respectively. Polymyxin B did not inhibit NADPH 
oxidase activation by FMLP ± CB in neutrophils, but reduced the effect of FMLP 
± CB in HL-60 cells by 42 and 554, respectively. The effects of retinoids on 
receptor-mediated 02 - formation depended on the absence or presence of CB in 
the assay mixtures: In the absence of CB, retinal enhanced 02 - formation by 
FMLP in both cell types up to 4.5-fold. In the presence of CB, retinal inhib- 
ited FMLP-induced 02" formation in neutrophils and stimulated the one in HL-60 
cells. Retinoic acid potentiated 02" formation induced by FMLP in both cell 
types. In contrast, retinoic acid inhibited receptor-mediated 02 - formation in 
the presence of CB. As was the case with NADPH oxidase activation by PMA, the 
one induced by FMLP ± CB in both cell types was completely prevented by TFP 
and W-7. 
DISCUSSION 
We demonstrate differential inhibition and stimulation of 02 - formation 
by PKC inhibitors, using various stimuli and two related cellular systems, 
possessing similar transmembrane signalling mechanisms. In agreement with pre- 
vious studies, we found that H-7 and polymyxin B did not substantially inhibit 
receptor-mediated activation processes in neutrophils [5,6]. However, these 
compounds substantially inhibited FMLP-induced 02 - formation in HL-60 cells. 
These differences may be explained, at least in part, by different permeation 
of these compounds into the cells and support the view that the effects of PKC 
inhibitors exhibit cell type specificity [9]. However, neither with H-7 nor 
with polymyxin B complete inhibition of 02" formation was observed regardless 
of the stimulus. Polymyxin B was recently reported not to inhibit PMA-induced 
protein phosphorylation in HL-60 cells [19]. One explanation for these results 
may be the possibility that H-7- and polymyxin B-insensitive PKC molecules me- 
diate cellular activation which may play a role in both PMA- and FMLP-induced 
activations of NADPH oxidase. However, even inhibition of receptor-mediated 
NADPH oxidase activation by these compounds in HL-6O cells does not necessar- 
i ly  imply that PKC is involved in this signalling process: At the high concen- 
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trations used in our study, polymxin B may also inhib i t  ion channels [20] and 
calmodulin-dependent processes [ i i ] .  In comparison, H-7 inhibits cyclic 
nucleotide- and calmodulin-dependent kinases [10], which may contribute to the 
inhibit ion of 02" formation. 
Even more d i f f i cu l t  to interprete are the results concerning retinoid- 
modulation of 02 - formation. In agreement with previous reports, retinoic acid 
inhibited 02" formation in neutrophils induced either with PMA or FMLP plus CB 
[21,22]. However, retinoids potentiated receptor-mediated activation of NADPH 
oxidase in the absence of CB. In addition, retinoids enhanced NADPH oxidase 
activation by PMA in HL-60 cells, indicating that retinoids do not generally 
antagonize the effects of phorbol esters [21]. Retinoids do not only inhibit  
but also stimulate PKC in vitro under certain experimental conditions [13,14, 
23]. In addition, retinoids were reported to activate NADPH oxidase in neutro- 
phils [24]. We found that retinoic acid and retinal did not induce 02 - forma- 
tion in HL-60 cells (data not shown). In neutrophils retinal at concentrations 
up to i00 ~M also did not activate NADPH oxidase, whereas retinoic acid (50 
~M) induced the formation of 16.9 ± 6.9 nmoles of 02-/107 cells/min (n=6). 
Thus, retinoids may act as activators or inhibitors of PKC in vivo, with their 
effects varyingwith the cell type and the experimental conditions. Finally, 
the finding that retinoids potentiated receptor-mediated activation of NADPH 
oxidase in the absence of CB suggests that these compounds exhibit CB-like 
properties [25]. 
In contrast to H-7, polymyxin B and retinoids, the dual PKC/calmodulin 
inhibitors,  TFP and W-7, completely inhibited 02 - formation without stimulus 
or cell type speci f ic i ty .  Thus, i t  may be tempting to speculate that calmodu- 
l in-  rather than PKC-mediated reactions are involved in NADPH oxidase activa- 
tion by PMA and FMLP [26]. There is, however, no additional evidence that PMA 
activates NADPH oxidase via calmodulin [2], Interestingly, i t  was recently re- 
ported that TFP and W-7 but not H-7 strongly inhibited the PKC- and calmodu- 
lin-independent activation of NADPH oxidase in cell-free systems [7,27]. These 
data suggest that W-7 and TFP may be potent inhibitors of NADPH oxidase per 
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se. This interpretation is also supported by our present results, showing that 
these compounds exhibited very untypical inhibitory profi les on NADPH oxidase 
activation in comparison to other PKC inhibitors.  
In conclusion, i t  appears d i f f i cu l t  to correlate inhibit ion or stimula- 
t ion of 02 - formation by various classes of PKC inhibitors with modulation of 
PKC act iv i ty  in vivo. Thus, studies with the PKC inhibitors presently avai- 
lable can apparently not elucidate the precise role of PKC in the course of 
NADPH oxidase activation. These results, however, do not exclude the possibi l-  
i ty  that potent and specific PKC inhibitors may provide valuable tools to elu- 
cidate the role of PKC in cel lular activation processes. 
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